1. Löwenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999; 341:1051–1062. PMID:
10502596.
Article
3. Teuffel O, Leibundgut K, Lehrnbecher T, Alonzo TA, Beyene J, Sung L. Anthracyclines during induction therapy in acute myeloid leukaemia: a systematic review and meta-analysis. Br J Haematol. 2013; 161:192–203. PMID:
23398482.
Article
4. Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009; 361:1249–1259. PMID:
19776406.
Article
5. Lee JH, Joo YD, Kim H, et al. A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia. Blood. 2011; 118:3832–3841. PMID:
21828126.
Article
6. Burnett AK, Russell NH, Hills RK, et al. A randomized comparison of daunorubicin 90 mg/m
2 vs 60 mg/m
2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood. 2015; 125:3878–3885. PMID:
25833957.
7. Pautas C, Merabet F, Thomas X, et al. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. J Clin Oncol. 2010; 28:808–814. PMID:
20048183.
Article
8. Luskin MR, Lee JW, Fernandez HF, et al. Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. Blood. 2016; 127:1551–1558. PMID:
26755712.
Article
9. Weick JK, Kopecky KJ, Appelbaum FR, et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood. 1996; 88:2841–2851. PMID:
8874180.
Article
10. Bishop JF, Matthews JP, Young GA, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood. 1996; 87:1710–1717. PMID:
8634416.
11. Bishop JF, Matthews JP, Young GA, Bradstock K, Lowenthal RM. Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and updated results of the Australian Leukemia Study Group. Leuk Lymphoma. 1998; 28:315–327. PMID:
9517503.
Article
12. Willemze R, Suciu S, Meloni G, et al. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial. J Clin Oncol. 2014; 32:219–228. PMID:
24297940.
Article
13. Li W, Gong X, Sun M, et al. High-dose cytarabine in acute myeloid leukemia treatment: a systematic review and meta-analysis. PLoS One. 2014; 9:e110153. PMID:
25299623.
Article
14. Shaffer LG, Slovak ML, Campbell LJ, editors. ISCN 2009: An International System for Human Cytogenetic Nomenclature. 2009. Basel, Switzerland: Karger.
15. Park HS, Kim DW, Kim CC, et al. Induction chemotherapy with idarubicin plus N4-behenoyl-1-beta-D-arabinofuranosylcytosine in acute myelogenous leukemia: a newly designed induction regimen--a prospective, cooperative multicenter study. Semin Hematol. 1996; 33(4 Suppl 3):24–29.
16. Yoon JH, Kim HJ, Park SS, et al. Long-term clinical outcomes of hematopoietic cell transplantation for intermediate-to-poor-risk acute myeloid leukemia during first remission according to available donor types. Oncotarget. 2017; 8:41590–41604. PMID:
28206975.
Article
17. Yoon JH, Kim HJ, Park SS, et al. Clinical outcome of autologous hematopoietic cell transplantation in adult patients with acute myeloid leukemia: Who may benefit from autologous hematopoietic cell transplantation? Biol Blood Marrow Transplant. 2017; 23:588–597. PMID:
28089879.
Article
18. Cho BS, Yoon JH, Shin SH, et al. Comparison of allogeneic stem cell transplantation from familial-mismatched/haploidentical donors and from unrelated donors in adults with high-risk acute myelogenous leukemia. Biol Blood Marrow Transplant. 2012; 18:1552–1563. PMID:
22516055.
Article
19. Kim HJ, Min WS, Eom KS, et al. Autologous stem cell transplantation using modified TAM or combination of triple-alkylating agents conditioning regimens as one of the post-remission treatments in patients with adult acute myeloid leukemia in first complete remission. Bone Marrow Transplant. 2004; 34:215–220. PMID:
15170169.
Article
20. Lee SE, Kim HJ, Min WS, et al. Favorable outcomes of intravenous busulfan, fludarabine, and 400 cGy total body irradiation-based reduced-intensity conditioning allogeneic stem cell transplantation for acute myelogenous leukemia with old age and/or co-morbidities. Int J Hematol. 2010; 92:342–350. PMID:
20694843.
21. Yahng SA, Kim JH, Jeon YW, et al. A well-tolerated regimen of 800 cGy TBI-fludarabine-busulfan-ATG for reliable engraftment after unmanipulated haploidentical peripheral blood stem cell transplantation in adult patients with acute myeloid leukemia. Biol Blood Marrow Transplant. 2015; 21:119–129. PMID:
25300871.
Article
22. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988; 16:1141–1154.
Article
23. Kimura K, Ohno R, Amaki I, et al. Phase I clinical and pharmacokinetic study of N4-behenoyl-1-beta-D-arabinofuranosylcytosine. Med Oncol Tumor Pharmacother. 1986; 3:15–24. PMID:
3702507.
Article
24. Kobayashi T, Miyawaki S, Tanimoto M, et al. Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group. J Clin Oncol. 1996; 14:204–213. PMID:
8558199.
Article
25. Campuzano-Zuluaga G, Deutsch Y, Salzberg M, et al. Routine interim disease assessment in patients undergoing induction chemotherapy for acute myeloid leukemia: Can we do better? Am J Hematol. 2016; 91:277–282. PMID:
26663264.
Article
26. Haferlach T, Kern W, Schoch C, et al. A new prognostic score for patients with acute myeloid leukemia based on cytogenetics and early blast clearance in trials of the German AML Cooperative Group. Haematologica. 2004; 89:408–418. PMID:
15075074.
27. Kern W, Haferlach T, Schoch C, et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. Blood. 2003; 101:64–70. PMID:
12393605.
Article
28. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med. 1994; 331:896–903. PMID:
8078551.
29. Fukushima T, Urasaki Y, Yamaguchi M, et al. A randomized comparison of modified intermediate-dose Ara-C versus high-dose ara-c in post-remission therapy for acute myeloid leukemia. Anticancer Res. 2012; 32:643–647. PMID:
22287757.
30. Löwenberg B, Pabst T, Vellenga E, et al. Cytarabine dose for acute myeloid leukemia. N Engl J Med. 2011; 364:1027–1036. PMID:
21410371.
Article